Acute lymphoblastic leukemia (ALL), also known as acute lymphocytic leukemia, is a rare blood cancer ...
€1,241.16
This Market Spotlight report covers the Zika virus market, comprising key pipeline therapies, clinical trials, ...
€1,241.16
This Market Spotlight report covers the Tuberculosis (TB) market, comprising key marketed and pipeline drugs, ...
€1,241.16
This Market Spotlight report covers the pancreatic cancer market, comprising key marketed and pipeline drugs, ...
€1,241.16
This Market Spotlight report covers the Hepatitis B market, comprising key marketed and pipeline drugs, ...
€1,241.16
This Market Spotlight report covers the Obesity market, comprising key marketed and pipeline drugs, clinical ...
€1,241.16
Digital’s potential to transform every aspect of the pharmaceutical value chain, from discovery to commercial, ...
€2,820.39
PharmaVitae explores and visualizes market dynamics in the Japan Pharma peer set out to 2027* ...
€2,825.10
Raxatrigine (Biogen) is a peripherally and centrally acting agent that inhibits sodium channels in a ...
€9,417.00
Nucynta (tapentadol; Collegium Pharmaceutical) first gained US Food and Drug Administration (FDA) approval in November ...
€9,417.00
Cebranopadol is a novel small molecule analgesic, which was discovered by Grünenthal. Cebranopadol represents a ...
€9,417.00
This Market Spotlight report covers the Erectile Dysfunction market, comprising key pipeline and marketed drugs, ...
€1,241.16
This Market Spotlight report covers the Hypogonadism market, comprising key marketed and pipeline drugs, clinical ...
€1,241.16
This Market Spotlight report covers the basal cell carcinoma market, comprising key marketed and pipeline ...
€1,241.16
This Market Spotlight report covers the esophageal cancer market, comprising key marketed and pipeline drugs, ...
€1,241.16
This Market Spotlight report covers the Hidradenitis Suppurativa market, comprising key marketed and pipeline drugs, ...
€1,241.16
Biogen’s chief medical officer says iPhone technology should in future be used for early warning ...
€94.17
This Market Spotlight report covers the Thyroid cancer market, comprising key pipeline and marketed drugs, ...
€1,241.16
This Market Spotlight report covers the Sjögren’s syndrome market, comprising key pipeline and marketed drugs, ...
€1,241.16
This Market Spotlight report covers the insomnia market, comprising key marketed and pipeline drugs, clinical ...
€1,241.16
This Market Spotlight report covers the irritable bowel syndrome (IBS) market, comprising key pipeline and ...
€1,241.16
This Market Spotlight report covers the Acne market, comprising key pipeline and marketed drugs, clinical ...
€1,241.16
This Market Spotlight report covers the Duchenne muscular dystrophy market, comprising key pipeline and marketed ...
€1,241.16
This Market Spotlight report covers the Celiac Disease market, comprising key pipeline drugs, clinical trials, ...
€1,241.16
This Market Spotlight report covers the sickle cell anemia market, comprising key marketed and pipeline ...
€1,241.16
This Market Spotlight report covers the cervical cancer market, comprising key pipeline and marketed drugs, ...
€1,241.16
This Market Spotlight report covers the myelodysplastic syndrome market, comprising key pipeline and marketed drugs, ...
€1,241.16
This Market Spotlight report covers the small cell lung cancer market, comprising key pipeline and ...
€1,241.16
This Market Spotlight report covers the Attention Deficit Hyperactivity Disorder (ADHD) market, comprising key marketed ...
€1,241.16
Zelboraf (vemurafenib; Roche/Chugai/Daiichi Sankyo) is an orally available agent that selectively targets the BRAF mutation. ...
€9,417.00
Tecentriq (atezolizumab; Roche/Chugai) is an antibody designed to target programmed death-ligand 1 (PD-L1) on tumor ...
€9,417.00
Tafinlar (dabrafenib; Novartis) is an adenosine triphosphate-competitive BRAF inhibitor with more than 100-fold selectivity for ...
€9,417.00
Opdivo is a fully human immunoglobulin G4 PD-1 immune checkpoint inhibitor that binds to the ...
€9,417.00
Eli Lilly’s Cymbalta (duloxetine), a serotonin-norepinephrine reuptake inhibitor, was initially approved in the US in ...
€9,417.00
Datamonitor interviewed an infectious diseases specialist based in the US Greater Washington DC area to ...
€564.08
Alzheimer's disease is an irreversible, progressive, neurodegenerative, and fatal disease that slowly affects memory, cognition, ...
€20,717.40
Binimetinib (Array BioPharma/Pierre Fabre/Ono Pharmaceutical) is an orally available inhibitor of mitogen-activated protein kinase kinase ...
€9,417.00
Meningitis is an infection of the meninges, the membranes surrounding the brain and spinal cord. ...
€20,717.40
Sign up to the